Lexaria Bioscience Corp. (LEXX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.30
- As of
Kresmion compiles this page from LEXX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Lexaria Bioscience Corp. (LEXX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-09.
See the full LEXX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LEXX on one page. Preview it with sample data, then open it live with a free account.
Preview the LEXX dossierActive events for LEXX
- medium13F: new position
CITADEL ADVISORS LLC new position in LEXX
- mediumEarnings above estimates
Q3-2026: Beat consensus by 7.7% - EPS $-0.08 vs $-0.0867 estimate
- mediumEarnings below estimates
Q3-2025: Missed consensus by 31.4% - EPS $-0.21 vs $-0.1598 estimate
- mediumEarnings below estimates
Q4-2025: Missed consensus by 31.4% - EPS $-0.21 vs $-0.1598 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 18.6% - EPS $-0.13 vs $-0.1598 estimate
FREE, NO ACCOUNT
Every event on LEXX, as it fires
You are seeing 5 of 7 events recorded on LEXX since 2026-06-05.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LEXX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 52886N406 · 2026Q2 | $88K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 52886N406 · 2026Q2 | $9K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LEXX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
LEXX mentioned in Kresmion daily briefs
LEXX against its peers
LEXX's operating margin of -1683.0% ranks in the 45th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | LEXX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 705923 USD | 259689 USD | 58 | 12 |
| Gross margin | 99.6% | n/a | n/a | 4 |
| Operating margin | -1683.0% | -640.7% | 45 | 9 |
| Net margin | -1686.0% | -682.5% | 41 | 10 |
| Return on equity | -398.1% | -151.2% | 13 | 19 |
Peers (22): AIM, APRE, VSBC, XCUR, TCRT, OSRH, NIKI, CSCIF, SKYE, CNSP, ALZN, IMRN, CURX, MTVA, BGMS, CMMB, VTGN, BOLT, RVPH, ACXP, SNTI, TRAW. Left out: FBLG (no annual filing), ENVB (no annual filing), CUBT (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (LEXX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LEXX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LEXX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.